WVE - Wave Life Sciences Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.08
-2.38 (-8.99%)
At close: 4:00PM EDT

24.08 0.00 (0.00%)
After hours: 4:53PM EDT

Stock chart is not supported by your current browser
Previous Close26.46
Open26.37
Bid23.72 x 800
Ask30.00 x 800
Day's Range23.95 - 26.37
52 Week Range22.25 - 56.00
Volume178,719
Avg. Volume296,666
Market Cap825.092M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-5.16
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.57
Trade prices are not sourced from all markets
  • Is Wave Life Sciences Ltd. (NASDAQ:WVE) Overpaying Its CEO?
    Simply Wall St.yesterday

    Is Wave Life Sciences Ltd. (NASDAQ:WVE) Overpaying Its CEO?

    In 2013 Paul Bolno was appointed CEO of Wave Life Sciences Ltd. (NASDAQ:WVE). First, this article will compare CEO...

  • Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
    Zacks17 days ago

    Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

    Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

  • GlobeNewswire21 days ago

    Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. “The initiation of the DYSTANCE 51 Phase 2/3 study represents a significant milestone for Wave and our DMD clinical program, as well as an important development for the families affected by Duchenne,” said Michael Panzara, MD, MPH, Chief Medical Officer of Wave Life Sciences.

  • GlobeNewswire21 days ago

    Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

    Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.

  • GlobeNewswirelast month

    Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara, MD, MPH, Chief Medical Officer, will present at the Parent Project Muscular Dystrophy (PPMD) 2019 Annual Conference in Orlando, Fla. on Saturday, June 29, 2019 at 12:00 p.m. ET. The presentation will include an overview of the ongoing clinical development of suvodirsen, the company’s investigational stereopure oligonucleotide for boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Suvodirsen is currently being studied in an open label extension (OLE) study, initiated in August 2018 with patients from the Phase 1 clinical trial.

  • Vertex enters Duchenne field with $245M buy of Exonics
    American City Business Journalslast month

    Vertex enters Duchenne field with $245M buy of Exonics

    Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.

  • Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Wave Life Sciences: 1Q Earnings Snapshot

    The Singapore-based company said it had a loss of $1.36 per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • GlobeNewswire2 months ago

    Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., May 10, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

  • Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?
    Insider Monkey3 months ago

    Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?

    Is WAVE Life Sciences Ltd. (NASDAQ:WVE) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known […]

  • Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks3 months ago

    Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?
    Simply Wall St.3 months ago

    What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?

    Wave Life Sciences Ltd.'s (NASDAQ:WVE) latest earnings announcement in December 2018 indicated that losses became smaller relative to the prior year's level - great news for investors...

  • Wave Life Sciences Plunges After DMD Study Data Readout
    Zacks3 months ago

    Wave Life Sciences Plunges After DMD Study Data Readout

    Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...

  • Associated Press3 months ago

    Qualcomm and Progressive jump while Wave Life Sciences drops

    Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...

  • Benzinga3 months ago

    Why Wave Life Sciences's Valuation Is Falling By 25%

    Small-cap biotech  Wave Life Sciences Ltd (NASDAQ: WVE ) — which fell  last week following a delay in the release of top-line data from its Huntington disease candidates — is once again under pressure ...

  • GlobeNewswire3 months ago

    Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The company also announced the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51.

  • Benzinga3 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • GlobeNewswire3 months ago

    Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference

    Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass., April.

  • TheStreet.com3 months ago

    Wave Life Sciences Plunges on Clinical Trial Data Delay

    shares were down more than 16% to $34.85 Wednesday after the biopharmaceutical company said it will delay the release of top-line data from the clinical trials of its Huntington's disease treatment candidate. "When we initiated these exciting clinical trials to explore the potential of an allele-selective approach to treating Huntington's disease, we set aggressive timelines for ourselves in recognition of the enormous need in the global Huntington's disease community. While we are disappointed that enrollment is not as fast as we anticipated, we are pleased that patient and physician interest in the trials remains high," said Dr. Michael Panzara, chief medical officer at Wave Life Sciences.

  • GlobeNewswire3 months ago

    Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today provided an update on the timing of the topline data readout from its ongoing PRECISION-HD program, which consists of two global Phase 1b/2a clinical trials evaluating investigational therapies WVE-120101 and WVE-120102 for patients with Huntington’s disease (HD). The company now expects to report topline clinical data from the PRECISION-HD program by the end of the year. This update is not due to a preclinical or clinical safety finding and the PRECISION-HD clinical program remains blinded.

  • Sarepta plans second Duchenne drug application this year
    American City Business Journals4 months ago

    Sarepta plans second Duchenne drug application this year

    With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.

  • GlobeNewswire4 months ago

    Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and progress for its Duchenne muscular dystrophy (DMD) programs will be shared at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference themed, “Progress in Motion,” April 13-17, 2019 in Orlando, Fla. This year the MDA annual conference will gather both healthcare providers and researchers together into one conference to discuss the latest in neuromuscular disease research and care.

  • Should You Be Worried About Insider Transactions At Wave Life Sciences Ltd. (NASDAQ:WVE)?
    Simply Wall St.4 months ago

    Should You Be Worried About Insider Transactions At Wave Life Sciences Ltd. (NASDAQ:WVE)?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • GlobeNewswire4 months ago

    Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

    CAMBRIDGE, Mass., March 06, 2019 -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.